We've teamed up with Just Giving to create a Striding for Survival fundraising campaign. Follow the link below and click the orange 'Start Fundraising' button on our Striding for Survival page to create your own Striding page that contributes to our campaign:
Striding for Survival – VIRTUAL
In light of the Coronavirus Global Pandemic, we have sadly had to cancel Striding for Survival at Painshill Park this year. However, that doesn't mean it's the end of Striding for Survival for 2020, as we've been working hard at making it VIRTUAL!
Let’s stride together on 6th June and remember those lost to pancreatic cancer and to support our work to improve early diagnosis and the quality of life for patients.
No matter where you are YOU and your lovely network can still Stride for Survival and make the difference for pancreatic cancer and PCA.
If you want to do your stride on another date that means something to you then you can too!
All you need to do is:
- Sign-up online with links below. You can choose between receiving a physical medal (£15) or a digital medal (£10)
- Set up your fundraising page here – share it with your friends
- Cover the distance of your choice and record it using a mileage age tracking app such as Strava or Runkeeper
- Upload proof of your mileage
- Receive your medal!
It really is that simple and we would love you to get on board and take part in our VIRTUAL Stride.
Sign up with PCA to receive:
- Fundraising pack and sponsorship forms
- Digital assets to share on your social media
- Finishers medal (on completion of your Stride!)
- Finishers certificate
- PCA Striding for Survival t-shirt to wear on the day
- Ongoing support from our dedicated fundraising team!
Sponsored by Immunovia AB
This years event is kindly sponsored by Immunovia AB: a diagnostic company who are developing highly accurate blood tests for the early detection of cancer and autoimmune diseases.
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
For more information, please visit www.immunovia.com.